Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Adverum Biotechnologies's Ixoberogene soroparvovec?
Ixoberogene soroparvovec is a gene therapy commercialized by Adverum Biotechnologies, with a leading Phase II program in Wet (Neovascular /...
Ixoberogene soroparvovec by Adverum Biotechnologies for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Ixoberogene soroparvovec is under clinical development by Adverum Biotechnologies and currently in Phase II for Wet (Neovascular / Exudative) Macular...
Risk adjusted net present value: What is the current valuation of Adverum Biotechnologies's Ixoberogene soroparvovec?
Ixoberogene soroparvovec is a gene therapy commercialized by Adverum Biotechnologies, with a leading Phase II program in Wet (Neovascular /...